Plasma-derived products and Creutzfeldt-Jakob disease: Comparison of legislation around the world

详细信息    查看全文

• 作者：Dr. A. Paret^a ; ^{audreyparet@hotmail.fr} ; Dr. J. Corny^b ; Dr. S. Prot-Labarthe^a ; ^c ; Prof. J.F. Bussiè ; res^b ; ^d ; Dr. I. Lopez^e ; Prof. O. Bourdon^a ; ^f ; ^g ; Dr. A. Rouault^a ; ^f ; ^g
• 关键词：Legislations comparison ; Patients and prescribers information ; Creutzfeldt-Jakob disease ; Plasma-derived products ; Blood donors selection
• 刊名：Le Pharmacien Hospitalier et Clinicien
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：51
• 期：4
• 页码：332-339
• 全文大小：353 K
• 卷排序：51

文摘

To analyze plasma-derived products (PD) traceability from donor selection to administration to patient. To compare PD recall legislations in France, United States (US), Canada and United Kingdom (UK) related to transmission of Creutzfeldt-Jakob disease (CJD). To develop a flowchart adapted to French context regarding information that should be given to patients.MethodLiterature research, consultation of national agencies and blood donation centers websites. Most recent laws and legislative texts were included.ResultsTwenty-five legislatives texts and 9 articles were retrieved. English donors and those who have stayed in UK more than 3 months (US) or 1 year (Europe) were excluded from plasma donations. In US and Canada, donors who lived during 5 years and more in France were also excluded. Europe and US recommended the recall of PD extracted from donors diagnosed with vCJD after donation. Recommendations concerning information to give to prescribers and patients were variable depending on the country analyzed.